JP6754353B2 - ハンチントンタンパク質のイメージング用プローブ - Google Patents
ハンチントンタンパク質のイメージング用プローブ Download PDFInfo
- Publication number
- JP6754353B2 JP6754353B2 JP2017511926A JP2017511926A JP6754353B2 JP 6754353 B2 JP6754353 B2 JP 6754353B2 JP 2017511926 A JP2017511926 A JP 2017511926A JP 2017511926 A JP2017511926 A JP 2017511926A JP 6754353 B2 JP6754353 B2 JP 6754353B2
- Authority
- JP
- Japan
- Prior art keywords
- pyridine
- methoxy
- carbonitrile
- benzofuran
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Optics & Photonics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Physics & Mathematics (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462043590P | 2014-08-29 | 2014-08-29 | |
| US62/043,590 | 2014-08-29 | ||
| PCT/US2015/047401 WO2016033440A1 (en) | 2014-08-29 | 2015-08-28 | Probes for imaging huntingtin protein |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017529340A JP2017529340A (ja) | 2017-10-05 |
| JP2017529340A5 JP2017529340A5 (https=) | 2018-10-11 |
| JP6754353B2 true JP6754353B2 (ja) | 2020-09-09 |
Family
ID=55400645
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017511926A Active JP6754353B2 (ja) | 2014-08-29 | 2015-08-28 | ハンチントンタンパク質のイメージング用プローブ |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US11104691B2 (https=) |
| EP (1) | EP3197277B1 (https=) |
| JP (1) | JP6754353B2 (https=) |
| KR (1) | KR102410733B1 (https=) |
| CN (1) | CN107105667B (https=) |
| AU (2) | AU2015308769A1 (https=) |
| BR (1) | BR112017004140B1 (https=) |
| CA (1) | CA2959533C (https=) |
| DK (1) | DK3197277T3 (https=) |
| EA (1) | EA039923B1 (https=) |
| ES (1) | ES2905095T3 (https=) |
| HR (1) | HRP20220001T1 (https=) |
| HU (1) | HUE057702T2 (https=) |
| IL (1) | IL250802B (https=) |
| MX (1) | MX386798B (https=) |
| PL (1) | PL3197277T3 (https=) |
| PT (1) | PT3197277T (https=) |
| SG (1) | SG11201701592SA (https=) |
| SI (1) | SI3197277T1 (https=) |
| WO (1) | WO2016033440A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE056957T2 (hu) | 2014-08-29 | 2022-04-28 | Chdi Foundation Inc | Próbák huntingtin fehérjét megjelenítõ képalkotásra |
| AU2015308709B2 (en) | 2014-08-29 | 2020-01-02 | Chdi Foundation, Inc. | Probes for imaging huntingtin protein |
| DK3197277T3 (da) | 2014-08-29 | 2022-01-31 | Chdi Foundation Inc | Prober til billeddannelse af huntingtin-protein |
| EP3186241B1 (en) | 2014-08-29 | 2020-10-07 | CHDI Foundation, Inc. | Probes for imaging huntington protein |
| PT3340796T (pt) | 2015-08-28 | 2021-07-28 | Chdi Foundation Inc | Sondas para imagens da proteína huntingtina |
| AU2018346962A1 (en) * | 2017-10-12 | 2020-05-28 | BCN Biosciences L.L.C. | Methods of treating radiation induced gastrointestinal syndrome |
| JP7619952B2 (ja) | 2019-02-25 | 2025-01-22 | シーエイチディーアイ ファウンデーション，インコーポレーテッド | 変異型ハンチンチンタンパク質を標的とするための化合物及びその使用 |
| WO2020227576A1 (en) | 2019-05-09 | 2020-11-12 | Genentech, Inc. | Regio-selective synthesis of imidazo[1,2-a]pyrimidines |
| CN114773312B (zh) * | 2021-10-29 | 2024-03-26 | 北京鑫诺康桥药物研究有限公司 | 一种盐酸阿罗洛尔中间体的制备工艺 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10050663A1 (de) * | 2000-10-13 | 2002-04-18 | Gruenenthal Gmbh | Verwendung von substituierten Imidazo[1,2-a]pyridin-, -pyrimidin- und pyrazin-3-yl-amin-Derivaten zur Herstellung von Medikamenten zur NOS-Inhibierung |
| EP1655287A1 (en) * | 2003-08-13 | 2006-05-10 | BF Research Institute, Inc. | Probe for diseases with amyloid accumulation, amyloid-staining agent, remedy and preventive for diseases with amyloid accumulation and diagnostic probe and staining agent for neurofibrillary change |
| CN101501033B (zh) * | 2006-06-21 | 2012-08-01 | 通用电气医疗有限公司 | 对淀粉状蛋白具有亲和性的化合物 |
| WO2008016648A2 (en) * | 2006-08-01 | 2008-02-07 | Cytokinetics, Incorporated | Certain chemical entities, compositions and methods |
| KR20090091287A (ko) * | 2006-11-17 | 2009-08-27 | 니혼 메디피직스 가부시키가이샤 | 신규 아밀로이드 친화성 화합물 |
| EP2098522B1 (en) * | 2006-11-30 | 2011-10-19 | Nihon Medi-Physics Co., Ltd. | Compounds having affinity for amyloid |
| EP2125800A1 (en) | 2007-01-22 | 2009-12-02 | AstraZeneca AB | Novel heteroaryl substituted imidazo ý1,2 -a¨pyridine derivatives |
| CN101909658A (zh) * | 2007-10-30 | 2010-12-08 | 日本医事物理股份有限公司 | 对淀粉样蛋白具有亲和性的新化合物的应用及制备方法 |
| FR2928923B1 (fr) * | 2008-03-21 | 2010-04-23 | Sanofi Aventis | Derives polysubstitues de 2-heteroaryl-6-phenyl-imidazo °1,2-a!pyridines, leur preparation et leur application en therapeutiques |
| CA2731738A1 (en) * | 2008-07-24 | 2010-01-28 | Siemens Medical Solutions Usa, Inc. | Imaging agents useful for identifying ad pathology |
| CN102224423B (zh) * | 2008-09-23 | 2014-10-22 | 维斯塔实验室有限公司 | 聚集的τ分子的配体 |
| WO2010141805A1 (en) * | 2009-06-05 | 2010-12-09 | Janssen Pharmaceutica Nv | Heterocyclic amides as modulators of trpa1 |
| CA2836872A1 (en) * | 2011-05-20 | 2012-11-29 | Nihon Medi-Physics Co., Ltd. | Novel compound having affinity for amyloid |
| JP5167436B2 (ja) * | 2011-06-24 | 2013-03-21 | 日本メジフィジックス株式会社 | 新規アミロイド親和性化合物 |
| JP2013237655A (ja) | 2012-05-17 | 2013-11-28 | Kyoto Univ | コンフォメーション病診断用分子プローブ |
| WO2014076021A1 (en) * | 2012-11-14 | 2014-05-22 | F. Hoffmann-La Roche Ag | Imidazopyridine derivatives |
| SI2970255T1 (sl) | 2013-03-14 | 2017-12-29 | Galapagos Nv | Spojine in farmacevtski sestavki le-teh za zdravljenje vnetnih motenj |
| JP6182668B2 (ja) * | 2013-09-26 | 2017-08-16 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 画像化ツールとしてのイミダゾ［１，２−ａ］ピリジン−７−アミン |
| DK3197277T3 (da) | 2014-08-29 | 2022-01-31 | Chdi Foundation Inc | Prober til billeddannelse af huntingtin-protein |
| EP3186241B1 (en) | 2014-08-29 | 2020-10-07 | CHDI Foundation, Inc. | Probes for imaging huntington protein |
| AU2015308709B2 (en) | 2014-08-29 | 2020-01-02 | Chdi Foundation, Inc. | Probes for imaging huntingtin protein |
| HUE056957T2 (hu) | 2014-08-29 | 2022-04-28 | Chdi Foundation Inc | Próbák huntingtin fehérjét megjelenítõ képalkotásra |
| PT3340796T (pt) | 2015-08-28 | 2021-07-28 | Chdi Foundation Inc | Sondas para imagens da proteína huntingtina |
-
2015
- 2015-08-28 DK DK15836261.6T patent/DK3197277T3/da active
- 2015-08-28 HU HUE15836261A patent/HUE057702T2/hu unknown
- 2015-08-28 KR KR1020177007881A patent/KR102410733B1/ko active Active
- 2015-08-28 EA EA201790400A patent/EA039923B1/ru unknown
- 2015-08-28 ES ES15836261T patent/ES2905095T3/es active Active
- 2015-08-28 WO PCT/US2015/047401 patent/WO2016033440A1/en not_active Ceased
- 2015-08-28 CA CA2959533A patent/CA2959533C/en active Active
- 2015-08-28 JP JP2017511926A patent/JP6754353B2/ja active Active
- 2015-08-28 HR HRP20220001TT patent/HRP20220001T1/hr unknown
- 2015-08-28 BR BR112017004140-5A patent/BR112017004140B1/pt active IP Right Grant
- 2015-08-28 PT PT158362616T patent/PT3197277T/pt unknown
- 2015-08-28 SI SI201531778T patent/SI3197277T1/sl unknown
- 2015-08-28 CN CN201580058314.XA patent/CN107105667B/zh active Active
- 2015-08-28 PL PL15836261T patent/PL3197277T3/pl unknown
- 2015-08-28 SG SG11201701592SA patent/SG11201701592SA/en unknown
- 2015-08-28 AU AU2015308769A patent/AU2015308769A1/en not_active Abandoned
- 2015-08-28 EP EP15836261.6A patent/EP3197277B1/en active Active
- 2015-08-28 US US15/507,203 patent/US11104691B2/en active Active
- 2015-08-28 MX MX2017002702A patent/MX386798B/es unknown
-
2017
- 2017-02-26 IL IL250802A patent/IL250802B/en active IP Right Grant
-
2019
- 2019-12-20 AU AU2019283999A patent/AU2019283999B2/en active Active
-
2021
- 2021-06-21 US US17/353,627 patent/US11851446B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7126541B2 (ja) | ハンチントンタンパク質のイメージング用プローブ | |
| JP6754353B2 (ja) | ハンチントンタンパク質のイメージング用プローブ | |
| JP7042940B2 (ja) | ハンチントンタンパク質のイメージング用プローブ | |
| JP6944929B2 (ja) | ハンチントンタンパク質のイメージング用プローブ | |
| US10907197B2 (en) | Probes for imaging huntingtin protein | |
| HK40110855A (zh) | 用於成像亨廷顿蛋白的探针 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RD01 | Notification of change of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7426 Effective date: 20180125 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20180125 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180828 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180828 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20191001 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20191225 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200214 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200728 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200821 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6754353 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |